Teva starts building new plant in Hungary
This article was originally published in Scrip
Teva Pharmaceutical Industries has begun building a new €65 million plant at its premises in Godollo near Budapest, Hungary. Its existing plant there generated revenues of more than Ft100 billion ($520.6 million) in 2008.
You may also be interested in...
FDA’s Teva Warning Letter Sets Agenda For Investigating, Remedying Sterility Failures
FDA has published a warning letter that not only provides detailed guidance for Teva’s ongoing remediation of sterility assurance failures at a plant in Godollo, Hungary, but also suggests a game plan for any manufacturer of sterile drug products that’s seeing signs of issues with aseptic operations.
Poland's new law fixes prices and trade mark-ups of reimbursed drugs
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
Global pharma boosts business in Russia - Why Russia (introduction)
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.